🔎 Trials Near Me

Domov › Rabdomiosarkom › Texas

Klinične študije za Rabdomiosarkom v Texas

9 študij za Rabdomiosarkom išče udeležence na lokacijah v Texas.

Mesta v Texas

Uradno besedilo študije (angleško)

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

  • University of Texas - MD Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 1
24 Months – 18 Years · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06441331

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • Children's Medical Center, Dallas
Vključevanje udeležencevFaza 1/2
Do 30 let · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06541262

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • in še 2
Vključevanje udeležencevFaza 3
Do 50 let · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT07466316

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

  • Texas Children's Hospital, Houston
Vključevanje udeležencevFaza 1
Starost 1–21 · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT04715191

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

  • Texas Children's Hospital, Houston
Vključevanje udeležencevFaza 1/2
Starost 1–30 · Vsi spoli · Posodobljeno 22. jul. 2026 · NCT06721689

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

  • Cook Children's Medical Center, Fort Worth
Vključevanje udeležencevFaza 2
Do 22 let · Vsi spoli · Posodobljeno 15. jun. 2026 · NCT06023641

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

  • The University of Texas Southwestern Medical Center, Dallas
  • Texas Children's Hospital, Houston
Vključevanje udeležencevFaza 1/2
6 Months – 30 Years · Vsi spoli · Posodobljeno 2. jun. 2026 · NCT04796012

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

  • Texas Children's Hospital, Houston
Vključevanje udeležencevFaza 1
Starost 1–25 · Vsi spoli · Posodobljeno 22. jan. 2026 · NCT04995003

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

  • Houston Methodist Hospital, Houston
Vključevanje udeležencevFaza 1
Do 21 let · Vsi spoli · Posodobljeno 3. nov. 2025 · NCT06198296

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.